Therapeutic Solutions International announced positive results of a pilot clinical trial in 20 subjects. In the study, ten subjects received placebo and ten received twice daily doses of QuadraMune for seven days. Blood monocytes were extracted and treated with SARS-CoV-2 spike protein in vitro for three time points.

A significantly decreased production of the inflammatory cytokine interleukin-6 was reported at all three timepoints.